Fargion Silvia, Fracanzani Anna Ludovica, Valenti Luca
Dipartimento di Medicina Interna, Ospedale Maggiore IRCCS, Università di Milano, Via F Sforza 35, 20122 Milan, Italy.
J Antimicrob Chemother. 2004 May;53(5):708-12. doi: 10.1093/jac/dkh170. Epub 2004 Apr 8.
Hepatitis C virus (HCV) infection is one of the leading causes of liver disease in the world. It is a common cause of cirrhosis and hepatocellular carcinoma (HCC), as well as the most common reason for liver transplantation. Thus, appropriate therapeutic approaches have a strong clinical impact on the morbidity and mortality of HCV-infected patients. In this review we outline the most recent results in the therapy of HCV chronic hepatitis. Patients with the best prognostic factors treated with combination therapy (peginterferon and ribavirin) obtained a sustained response rate of 80-95%. We also provide some hints on the most promising results of the newest therapeutic options, which include molecules that inhibit specific enzymes, such as inhibitors of serine proteases, which are now in preclinical or early phase human trials. Host factors influencing the rate of response are also outlined.
丙型肝炎病毒（HCV）感染是全球肝病的主要病因之一。它是肝硬化和肝细胞癌（HCC）的常见病因，也是肝移植最常见的原因。因此，适当的治疗方法对HCV感染患者的发病率和死亡率有重大临床影响。在本综述中，我们概述了HCV慢性肝炎治疗的最新结果。采用联合治疗（聚乙二醇干扰素和利巴韦林）治疗且具有最佳预后因素的患者获得了80%-95%的持续应答率。我们还提供了一些关于最新治疗选择最有前景结果的提示，这些最新治疗选择包括抑制特定酶的分子，如丝氨酸蛋白酶抑制剂，目前正处于临床前或早期人体试验阶段。本文还概述了影响应答率的宿主因素。
